vs

Side-by-side financial comparison of NU SKIN ENTERPRISES, INC. (NUS) and Wellgistics Health, Inc. (WGRX). Click either name above to swap in a different company.

NU SKIN ENTERPRISES, INC. is the larger business by last-quarter revenue ($370.3M vs $1.7M, roughly 221.7× Wellgistics Health, Inc.). NU SKIN ENTERPRISES, INC. runs the higher net margin — 3.9% vs -1667.2%, a 1671.1% gap on every dollar of revenue.

Nu Skin Enterprises, Inc. is an American multilevel marketing company that develops and sells personal care products and dietary and nutritional supplements. Under the Nu Skin and Pharmanex brands, the company sells its products in 54 markets through a network of approximately 1.2 million independent distributors.

Wellgistics Health, Inc. is a U.S.-headquartered healthcare services firm focused on the distribution of prescription pharmaceuticals, over-the-counter medications, and medical supplies. Its key customer segments include retail pharmacies, long-term care facilities, and independent healthcare providers across the domestic market.

NUS vs WGRX — Head-to-Head

Bigger by revenue
NUS
NUS
221.7× larger
NUS
$370.3M
$1.7M
WGRX
Higher net margin
NUS
NUS
1671.1% more per $
NUS
3.9%
-1667.2%
WGRX

Income Statement — Q4 2025 vs Q4 2025

Metric
NUS
NUS
WGRX
WGRX
Revenue
$370.3M
$1.7M
Net Profit
$14.5M
$-27.9M
Gross Margin
70.7%
-470.2%
Operating Margin
6.3%
-1517.5%
Net Margin
3.9%
-1667.2%
Revenue YoY
-16.9%
Net Profit YoY
140.1%
EPS (diluted)
$0.27
$-0.24

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
NUS
NUS
WGRX
WGRX
Q4 25
$370.3M
$1.7M
Q3 25
$364.2M
$3.0M
Q2 25
$386.1M
$7.8M
Q1 25
$364.5M
$10.9M
Q4 24
$445.6M
Q3 24
$430.1M
Q2 24
$439.1M
Q1 24
$417.3M
Net Profit
NUS
NUS
WGRX
WGRX
Q4 25
$14.5M
$-27.9M
Q3 25
$17.1M
$-34.3M
Q2 25
$21.1M
$-6.7M
Q1 25
$107.5M
$-32.4M
Q4 24
$-36.1M
Q3 24
$8.3M
Q2 24
$-118.3M
Q1 24
$-533.0K
Gross Margin
NUS
NUS
WGRX
WGRX
Q4 25
70.7%
-470.2%
Q3 25
70.5%
7.7%
Q2 25
68.8%
6.5%
Q1 25
67.8%
6.4%
Q4 24
62.7%
Q3 24
70.1%
Q2 24
70.0%
Q1 24
70.5%
Operating Margin
NUS
NUS
WGRX
WGRX
Q4 25
6.3%
-1517.5%
Q3 25
5.9%
-1047.1%
Q2 25
8.0%
-70.6%
Q1 25
-2.7%
-288.6%
Q4 24
-11.9%
Q3 24
4.2%
Q2 24
-28.6%
Q1 24
2.1%
Net Margin
NUS
NUS
WGRX
WGRX
Q4 25
3.9%
-1667.2%
Q3 25
4.7%
-1139.0%
Q2 25
5.5%
-85.6%
Q1 25
29.5%
-298.5%
Q4 24
-8.1%
Q3 24
1.9%
Q2 24
-26.9%
Q1 24
-0.1%
EPS (diluted)
NUS
NUS
WGRX
WGRX
Q4 25
$0.27
$-0.24
Q3 25
$0.34
$-0.46
Q2 25
$0.43
$-0.11
Q1 25
$2.14
$-0.62
Q4 24
$-0.73
Q3 24
$0.17
Q2 24
$-2.38
Q1 24
$-0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
NUS
NUS
WGRX
WGRX
Cash + ST InvestmentsLiquidity on hand
$239.8M
$42.6K
Total DebtLower is stronger
$23.5M
Stockholders' EquityBook value
$805.2M
$-12.4M
Total Assets
$1.4B
$30.5M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
NUS
NUS
WGRX
WGRX
Q4 25
$239.8M
$42.6K
Q3 25
$253.0M
$4.2M
Q2 25
$265.4M
$419.9K
Q1 25
$213.6M
$2.5M
Q4 24
$198.0M
Q3 24
$237.8M
Q2 24
$232.9M
Q1 24
$221.2M
Total Debt
NUS
NUS
WGRX
WGRX
Q4 25
$23.5M
Q3 25
$24.8M
Q2 25
$23.3M
Q1 25
$24.1M
Q4 24
Q3 24
Q2 24
Q1 24
Stockholders' Equity
NUS
NUS
WGRX
WGRX
Q4 25
$805.2M
$-12.4M
Q3 25
$799.8M
$6.8M
Q2 25
$787.8M
$905.3K
Q1 25
$754.0M
$4.5M
Q4 24
$651.5M
Q3 24
$706.9M
Q2 24
$686.2M
Q1 24
$810.2M
Total Assets
NUS
NUS
WGRX
WGRX
Q4 25
$1.4B
$30.5M
Q3 25
$1.4B
$52.8M
Q2 25
$1.4B
$54.2M
Q1 25
$1.4B
$58.1M
Q4 24
$1.5B
Q3 24
$1.6B
Q2 24
$1.6B
Q1 24
$1.7B
Debt / Equity
NUS
NUS
WGRX
WGRX
Q4 25
Q3 25
3.66×
Q2 25
25.72×
Q1 25
5.39×
Q4 24
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
NUS
NUS
WGRX
WGRX
Operating Cash FlowLast quarter
$16.6M
$-6.3M
Free Cash FlowOCF − Capex
$5.9M
FCF MarginFCF / Revenue
1.6%
Capex IntensityCapex / Revenue
2.9%
Cash ConversionOCF / Net Profit
1.15×
TTM Free Cash FlowTrailing 4 quarters
$46.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
NUS
NUS
WGRX
WGRX
Q4 25
$16.6M
$-6.3M
Q3 25
$27.5M
$-1.1M
Q2 25
$35.8M
$-2.1M
Q1 25
$389.0K
$-1.3M
Q4 24
$25.8M
Q3 24
$31.4M
Q2 24
$51.2M
Q1 24
$3.3M
Free Cash Flow
NUS
NUS
WGRX
WGRX
Q4 25
$5.9M
Q3 25
$17.6M
Q2 25
$35.8M
Q1 25
$-13.2M
Q4 24
$13.2M
Q3 24
$22.8M
Q2 24
$43.1M
Q1 24
$-9.0M
FCF Margin
NUS
NUS
WGRX
WGRX
Q4 25
1.6%
Q3 25
4.8%
Q2 25
9.3%
Q1 25
-3.6%
Q4 24
3.0%
Q3 24
5.3%
Q2 24
9.8%
Q1 24
-2.1%
Capex Intensity
NUS
NUS
WGRX
WGRX
Q4 25
2.9%
Q3 25
2.7%
Q2 25
0.0%
Q1 25
3.7%
Q4 24
2.8%
Q3 24
2.0%
Q2 24
1.9%
Q1 24
2.9%
Cash Conversion
NUS
NUS
WGRX
WGRX
Q4 25
1.15×
Q3 25
1.61×
Q2 25
1.69×
Q1 25
0.00×
Q4 24
Q3 24
3.79×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

NUS
NUS

Other$161.9M44%
Mainland China Segment$52.0M14%
Southeast Asia Pacific Segment$50.5M14%
Europe And Africa Segment$41.8M11%
Hong Kong Taiwan Segment$29.6M8%
South Korea Segment$28.4M8%
Rhyz Other Segment$6.1M2%

WGRX
WGRX

Segment breakdown not available.

Related Comparisons